CoChat
Sign Up
Cited by 1,051

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

Ott, Marion G, Schmidt, Manfred, Schwarzwaelder, Kerstin, Stein, Stefan, Siler, Ulrich, Koehl, Ulrike, Glimm, Hanno, Kühlcke, Klaus, Schilz, Andrea, Kunkel, Hana, Naundorf, Sonja, Brinkmann, Andrea, Deichmann, Annette, Fischer, Marlene, Ball, Claudia, Pilz, Ingo, Dunbar, Cynthia, Du, Yang, Jenkins, Nancy A, Copeland, Neal G, Lüthi, Ursula, Hassan, Moustapha, Thrasher, Adrian J, Hoelzer, Dieter, von Kalle, Christof, Seger, Reinhard, Grez, Manuel·2006·Nature Medicine
DOI 10.1038/nm1393
Open this paper in CoChat — free account

Abstract

Gene transfer into hematopoietic stem cells has been used successfully for correcting lymphoid but not myeloid immunodeficiencies. Here we report on two adults who received gene therapy after nonmyeloablative bone marrow conditioning for the treatment of X-linked chronic granulomatous disease (X-CGD), a primary immunodeficiency caused by a defect in the oxidative antimicrobial activity of phagocytes resulting from mutations in gp91(phox). We detected substantial gene transfer in both individuals' neutrophils that lead to a large number of functionally corrected phagocytes and notable clinical improvement. Large-scale retroviral integration site-distribution analysis showed activating insertions in MDS1-EVI1, PRDM16 or SETBP1 that had influenced regulation of long-term hematopoiesis by expanding gene-corrected myelopoiesis three- to four-fold in both individuals. Although insertional influences have probably reinforced the therapeutic efficacy in this trial, our results suggest that gene therapy in combination with bone marrow conditioning can be successfully used to treat inherited diseases affecting the myeloid compartment such as CGD.

Overview

Integrity signals

Registry

Crossref · 10.1038/nm1393

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 46

  1. Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672 (2000). · DOI · Paper page
  2. Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413 (2002). · DOI · Paper page
  3. Hacein-Bey-Abina, S. et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185–1193 (2002). · DOI
  4. Gaspar, H.B. et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181–2187 (2004). · DOI
  5. Malech, H.L. et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 94, 12133–12138 (1997). · DOI
  6. Dunbar, C.E. et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9, 2629–2640 (1998). · DOI
  7. Kohn, D.B. et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 4, 775–780 (1998). · DOI
  8. Malech, H.L., Choi, U. & Brenner, S. Progress toward effective gene therapy for chronic granulomatous disease. Jpn. J. Infect. Dis. 57, 27–28 (2004).
  9. Barese, C.N., Goebel, W.S. & Dinauer, M.C. Gene therapy for chronic granulomatous disease. Expert Opin. Biol. Ther. 4, 1423–1434 (2004). · DOI
  10. Roos, D. The genetic basis of chronic granulomatous disease. Immunol. Rev. 138, 121–157 (1994). · DOI
  11. Segal, A.W. The NADPH oxidase and chronic granulomatous disease. Mol. Med. Today 2, 129–135 (1996). · DOI
  12. Segal, B.H., Leto, T.L., Gallin, J.I., Malech, H.L. & Holland, S.M. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79, 170–200 (2000). · DOI
  13. Heyworth, P.G., Cross, A.R. & Curnutte, J.T. Chronic granulomatous disease. Curr. Opin. Immunol. 15, 578–584 (2003). · DOI · Paper page
  14. Winkelstein, J.A. et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79, 155–169 (2000). · DOI · Paper page
  15. Seger, R.A. et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 100, 4344–4350 (2002). · DOI
  16. Mardiney, M., 3rd et al. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. Blood 89, 2268–2275 (1997). · DOI
  17. Dinauer, M.C., Li, L.L., Bjorgvinsdottir, H., Ding, C. & Pech, N. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Blood 94, 914–922 (1999). · DOI
  18. Sadat, M.A. et al. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker. Hum. Gene Ther. 14, 651–666 (2003). · DOI
  19. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003). · DOI · Paper page
  20. Baum, C. et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther. 9, 5–13 (2004). · DOI
  21. von Kalle, C. et al. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. Semin. Hematol. 41, 303–318 (2004). · DOI
  22. Bjorgvinsdottir, H. et al. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 89, 41–48 (1997). · DOI
  23. Schmidt, M. et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 100, 2737–2743 (2002). · DOI
  24. Schmidt, M. et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat. Med. 9, 463–468 (2003). · DOI
  25. Suzuki, T. New genes involved in cancer identified by retroviral tagging. Nat. Genet. 32, 166–174 (2004). · DOI
  26. Yamauchi, A. et al. Location of the epitope for 7D5, a monoclonal antibody raised against human flavocytochrome b558, to the extracellular peptide portion of primate gp91phox. Microbiol. Immunol. 45, 249–257 (2001). · DOI
  27. Mayo, L.A. & Curnutte, J.T. Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. Methods Enzymol. 186, 567–575 (1990). · DOI
  28. Hamers, M.N., Bot, A.A., Weening, R.S., Sips, H.J. & Roos, D. Kinetics and mechanism of the bactericidal action of human neutrophils against Escherichia coli. Blood 64, 635–641 (1984). · DOI
  29. Rex, J.H., Bennett, J.E., Gallin, J.I., Malech, H.L. & Melnick, D.A. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J. Infect. Dis. 162, 523–528 (1990). · DOI
  30. Hassan, M. et al. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. Cancer Chemother. Pharmacol. 42, 471–478 (1998). · DOI
  31. Hassan, Z. et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant. 27, 479–485 (2001). · DOI
  32. Du, Y., Jenkins, N.A. & Copeland, N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106, 3932–3939 (2005). · DOI
  33. Kustikova, O. et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308, 1171–1174 (2005). · DOI · Paper page
  34. Baum, C., Hegewisch-Becker, S., Eckert, H.G., Stocking, C. & Ostertag, W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69, 7541–7547 (1995). · DOI
  35. Thrasher, A.J. et al. Failure of SCID-X1 gene therapy in older patients. Blood 105, 4255–4257 (2005). · DOI
  36. Buonamici, S. et al. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Invest. 114, 713–719 (2004). · DOI
  37. Johansson, B., Fioretos, T. & Mitelman, F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 107, 76–94 (2002). · DOI
  38. Li, Z. et al. Murine leukemia induced by retroviral gene marking. Science 296, 497 (2002). · DOI · Paper page
  39. Buonamici, S., Chakraborty, S., Senyuk, V. & Nucifora, G. The role of EVI1 in normal and leukemic cells. Blood Cells Mol. Dis. 31, 206–212 (2003). · DOI
  40. Calmels, B. et al. Recurrent retroviral vector integration at the MDS1–EVI1 locus in rhesus long-term repopulating hematopoietic stem cells. Blood 106, 2530–2533 (2005). · DOI
  41. Glimm, H. et al. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood 106, 893–898 (2005). · DOI
  42. Dinauer, M.C., Gifford, M.A., Pech, N., Li, L.L. & Emshwiller, P. Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood 97, 3738–3745 (2001). · DOI
  43. Mills, E.L., Rholl, K.S. & Quie, P.G. X-linked inheritance in females with chronic granulomatous disease. J. Clin. Invest. 66, 332–340 (1980). · DOI
  44. Johnston, R.B., 3rd, Harbeck, R.J. & Johnston, R.B., Jr. Recurrent severe infections in a girl with apparently variable expression of mosaicism for chronic granulomatous disease. J. Pediatr. 106, 50–55 (1985). · DOI
  45. Rosen-Wolff, A. et al. Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization. Ann. Hematol. 80, 113–115 (2001). · DOI
  46. Wolach, B., Scharf, Y., Gavrieli, R., de Boer, M. & Roos, D. Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood 105, 61–66 (2005). · DOI

Cited by

Metadata

Authors
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., Naundorf, S., Brinkmann, A., Deichmann, A., Fischer, M., Ball, C., Pilz, I., Dunbar, C., Du, Y., Jenkins, N. A., Copeland, N. G., Lüthi, U., Hassan, M., Thrasher, A. J., Hoelzer, D., von Kalle, C., Seger, R., & Grez, M.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2006-04
Volume
12
Issue
4
Pages
401-409
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/nm1393
Cited by
1,051
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review